Renal Denervation in a Hypertensive Patient With End-Stage Renal Disease and Small Arteries: A Direction for Future Research

Journal of Clinical Hypertension

Volumn 14, Issue 11, 2012, Pages 799-801

  Ott, Christian ^a   Schmid, Axel ^a   Ditting, Tilmann ^a   Sobotka, Paul A ^b,c   Veelken, Roland ^a   Uder, Michael ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b OHIO STATE UNIVERSITY   (United States)

^c Coridea NC1 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; VASODILATOR AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE MONITORING; CASE REPORT; CATHETER; CATHETERIZATION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY DENERVATION; KIDNEY FAILURE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENAL ARTERY; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; CATHETER ABLATION; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; RENAL ARTERY; RENAL DIALYSIS;

EID: 84868573128     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12017     Document Type: Article

References (10)

1. Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195-1201.
2. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-1979.
3. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878-882.
4. Rafiq K, Noma T, Fujisawa Y, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation. 2012;125:1402-1413.
5. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
6. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
7. Prochnau D, Lauten A, Busch M, et al. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int J Cardiol. 2012;154:e29-e30.
8. Di Daniele N, De Francesco M, Violo L, et al. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant. 2012;27:1689-1690.
9. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
10. Ditting T, Freisinger W, Siegel K, et al. Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? Hypertension. 2012;59:467-476.